3Mann DL,Bristow MR.Mechanisms and models in heart failure:the biomechanical model and beyond.Circulation,2005,111:2837-2849.
4Chaneey AL,Brower GL,Peterson JT,et al.Effeets of Matrix metalloproteinase inhibition on ventrieular remodeling due to volume overload.Cireulation,2002,105:1983-1988.
5Romanic AM,Burbs CL,Gout B,et al.Matrix metalloproteinase expression in cardiac myoeytes following myoeardial infarction in the rabbit.Life Sei,2001,68:799-814.
6Soejima H,Ogawa H,Sakamoto T,et al.Icreased serum Matrix metalloproteinase-1 concentration Prediets advanced left ventricular Remodel in Parients with acute myocardial infaretion.Cire,2003,67:301-304.
7Pfeffer MA,Lamas GA,Vaughan DE,et al.Effect of captoppril on progressive ventricular dilatation after anterior myocardial infarction.N Engl J Med,1998,319:80-86.
8Bhakta S,Dunlap ME.Angiotensin-receptor blockers in heart failure:evidence from the CHARM trial.Cleveland Clinic Journal of Medicine,2004,71:665-673.
9Henry K,Peter C,Csaba F,et al.Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure:results from Val-HeFT.Eur J Heart Fail,2004,6:937-945.
10Zannad F,Alla F,Dousset B,et al.Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure:insights from the randomized aldactone evaluation study (RALES).Rales Investigators.Circulation,2000,102:2700-2706.
